A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Conditions
Other Female Genital | Ovary
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
This phase II trial studies how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back (recurrent). Chemotherapy drugs, such as tazemetostat, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
- Trial withNRG Oncology Foundation, Inc.
- Start Date05/10/2022
- End Date01/31/2025
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Alessandro Santin, MD
- Anamika Katoch, MD
- Andrea Martelli
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Elena Ratner, MD
- Gary Altwerger, MD
- Gulden Menderes, MD
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jason Haldas, MD
- Jaykumar Thumar, MBBS, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Katherine Harvey, MD, MPH
- Kelsey Martin, MD
- Kert Sabbath, MD, FACP
- Khanh Nguyen, MD
- Madeline Santiago
- Masoud Azodi, MD
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Pawan Karanam, MD
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Vaagn Andikyan, MD
- Victor Chang, MD
- Wajih Kidwai, MD, FACP
- Zia Rahman, MD
- Last Updated05/11/2022
- Study HIC#2000025592